DOCSLIB.ORG

3Rd Macquarie Neurodegeneration Meeting 28-29 OCTOBER 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
3Rd Macquarie Neurodegeneration Meeting 28-29 OCTOBER 2020 CENTRE FOR MOTOR NEURONEDISEASE RESEARCH Faculty of Medicine, Health and Human Sciences 3rd Macquarie Neurodegeneration Meeting 28-29 OCTOBER 2020 AN EVENT FOR AUSTRALIAN NEUROSCIENTISTS TO SHOWCASE THEIR RESEARCH AND TO STIMULATE CONVERSATION AND FOSTER COLLABORATION TO DEVELOP TREATMENTS FOR DISEASES INCLUDING MOTOR NEURON DISEASE, ALZHEIMER’S DISEASE, FRONTOTEMPORAL DEMENTIA, PARKINSON’S DISEASE AND OTHER DEGENERATIVE BRAIN DISORDERS. Our Sponsor We are incredibly thankful to our sponsor for their support of the Macquarie Neurodegeneration Meeting Gain a new perspective on the nervous system and accelerate discovery. Explore 10x Genomics Solutions for neuroscience in this short video. 2 Our Sponsor 3 Our Sponsor 4 Welcome The Macquarie Neurodegeneration Meeting is an annual event hosted by the Centre for Motor Neuron Disease Research, Macquarie University. The aim of this event is for Australian neuroscientists to showcase their research and to stimulate conversation and foster collaboration to develop treatments for diseases including motor neuron disease, Alzheimer’s disease, frontal temporal dementia, Parkinson’s disease and other degenerative brain disorders. We welcome your involvement and hope the day provides inspiration and assists in fostering collaboration and connections in the neurodegeneration research community. Yours Sincerely, The Conference Organising Committee COMMITTEE MEMBERS Centre for Motor Neuron Disease Research Professor Julie Atkin Co-Director Professor Ian Blair Co-Director Christina Cassidy Centre Administrator Flora Cheng Research Assistant Dr Lyndal Henden Postdoctoral Research Fellow Research Dr Emily McCaan Postdoctoral Research Fellow Research Dr Prachi Mehta Research Officer Dr Sonam Parakh Postdoctoral Research Fellow 5 Program Conference Program WEDNESDAY OCTOBER 28TH 2020 Opening 2:00 pm – 2:05 pm Webinar Opening Welcome remarks by Professor Julie Atkin Co-Director Centre for Motor Neuron Disease Research, Macquarie University Session 1 Chair – Dr Emily Don 2:05 pm – 2:35 pm Professor Neil Cashman The Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Canada TDP-43 Misfolding-Specific Antibodies in Treatment of TDP-43 Mediated Diseases (30min) 2:35 pm – 2:50pm Dr Sophia Luikinga The Florey Institute of Neuroscience and Mental Health Ambroxol as novel therapeutic intervention to improve motor function in a mouse model of ALS (15min) 2:50 pm – 3:20 pm Professor Gilles Guillemin Centre for Motor Neuron Disease Research, Macquarie University Overview of the involvement of the kynurenine pathway in neuroinflammatory diseases. Applications for prognosis and treatment (30min) 3: 20 pm – 3:35 pm Dr Emily McCann Centre for Motor Neuron Disease Research, Macquarie University Implicating novel genetic variation in ALS through the analysis of disease discordant monozygotic twins (15min) Break 3:35 pm –4:20 pm Time to view Posters https://www.mq.edu.au/research/research-centres-groups-and- facilities/healthy-people/centres/macquarie-university-centre- for-motor-neuron-disease-research/conference 6 Program Session 2 Chair – Dr Alison Hogan 4:20 pm – 4:35 pm Ms Sarah El-Wahsh Faculty of Medicine and Health, Speech Pathology Department, The University of Sydney Perspectives from the patient: communication symptoms, their impact, and speech pathology services in multiple sclerosis (15 min) 4:35 pm – 4:50 pm Dr Léonie Borne Systems Neuroscience Group, School of Psychology, Faculty of Science, University of Newcastle Modes of covariation between cortical anatomy and multi- domain cognitive function in healthy mid-life adults predict mild cognitive impairment and Alzheimer’s dementia (5min) 4:50 pm – 4.55 pm Dr Cindy Maurel Centre for Motor Neuron Disease Research, Macquarie University The unexplored effects of SUMOylation on TDP-43 aggregation and sub-cellular localization (5 min) 4:55 pm – 5:00 pm Dr Lyndal Henden Centre for Motor Neuron Disease Research, Macquarie University Identity by descent analysis links SOD1 familial and sporadic ALS cases (5 min) Professor Flaviano Giorgini 5.00 pm – 5.30 pm Department of Genetics and Genome Biology, University of Leicester, UK The kynurenine pathway and Huntington’s disease: from mechanisms to therapeutics (30 min) Professor Ammar Al-Chalabi 5.30 pm – 6.00 pm Kings College London, UK Understanding the causes of motor neuron disease (30 min) End Session – Reminder Posters available to view overnight on our website https://www.mq.edu.au/research/research-centres-groups-and-facilities/healthy- people/centres/macquarie-university-centre-for-motor-neuron-disease- research/conference 7 Program Conference Program THUSDAY OCTOBER 29TH 2020 Session 3 Chair – Dr Shelley Forrest 9:00 am – 9:05 am Welcome by Professor Ian Blair Co-Director - Centre for Motor Neuron Disease Research, Macquarie University 9:05 am – 9:20 am Dr Rachel Atkinson from Wicking Dementia Research and Education Centre, University of Tasmania New model approaches for understanding axon degeneration in ALS (15min) 9:20 am – 9:35am Dr Mouna Haidar from The Florey Institute of Neuroscience and Mental Health, University of Melbourne Modelling cortical hyperexcitability in amyotrophic lateral sclerosis using chemogenetics (15min) 9:35 am – 9: 50 am Ms Katherine Jane Robinson from Centre for Motor Neuron Disease Research, Macquarie University Pathological expansion of ATXN3 alters memory and anxiety-like behaviours in a mouse model of Machado Joseph Disease/Spinocerebellar Ataxia Type 3 (15min) 9:50 am – 10:20 am Dr Arne Ittner from Dementia Research Centre, Macquarie University Protein kinases and tau phosphorylation in memory (30min) 10:20 am – 10:25 am Mrs Barbora Fulopova from University of Tasmania Differential patterns of cortical connectivity and beta amyloid deposition in APP/PS1 mice relative to ageing and the effects of midlife environmental enrichment (5min) Break 10:25 am – 11:00 am Time to view Posters https://www.mq.edu.au/research/research-centres-groups-and- facilities/healthy-people/centres/macquarie-university-centre- for-motor-neuron-disease-research/conference 8 Program Session 4 Chair – Dr Jennifer Fifita 11:00 am – 11:30 am Professor Anna King from University of Tasmania Blood biomarkers of neurodegeneration (30min) 11:30 am – 11:45 am Dr Lisa Oyston from Brain and Mind Centre, University of Sydney Determining the pathogenicity of TBK1 missense variants in FTD and ALS (15min) 11:45 am – 11:50 am Ms Marina Ulanova from Centre for Healthy Brain Ageing, UNSW Magnetic nanoparticles as MRI contrast agents for the diagnosis of Alzheimer’s Disease (5min) 11:50 am – 11:55 am Associate Professor Alison Canty from Wicking Dementia Research and Education Centre, University of Tasmania In vivo imaging of injured cortical axons reveals a rapid onset form of Wallerian degeneration (5min) 11:55 am – 12:00 pm Mr Andres Vidal-Itriago from Centre for Motor Neuron Disease Research, Macquarie University The missing link: Investigating the physiological traits of microglia during neurodegeneration (5min) 12:00 pm – 12:30 pm Professor Colin L Masters Laurette Professor of Dementia Research from The Florey Institute, The University of Melbourne The molecular origins of Alzheimer’s disease: when does it start and what strategies for primary prevention? (30min) Close of Presentations 12:30 pm – 12:35 pm Closing remarks by Professor Patrick McNeil Deputy Vice-Chancellor (Medicine and Health) and Executive Dean of Faculty of Medicine, Health and Human Science, Macquarie University 12:35 pm – 12:45 pm Prize Presentation 9 Invited Speakers Professor Ammar Al-Chalabi PROFESSOR OF NEUROLOGY King's College London Ammar Al-Chalabi is professor of neurology and complex disease genetics at King’s College London, consultant neurologist at King’s College Hospital and Deputy Editor, Brain. His research focuses on understanding the causes and modifiers of motor neuron disease and how these can be used to find effective treatments. Professor Neil Cashman PROFESSOR OF MEDICINE University of British Columbia Dr. Neil Cashman is Professor of Medicine at the University of British Columbia, where his basic research is focused on the role of protein misfolding in Alzheimer’s and Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). He serves as a Director of the ALS Centre Clinic at G.F. Strong Hospital. He is a neurologist-neuroscientist- entrepreneur who holds leadership positions in these three career domains. Two central ideas inform his scientific and translational work: first, that neurodegenerative diseases are due to prion-like propagated protein misfolding, and second, that antibodies are well suited to specifically bind to misfolded proteins while sparing normal proteins from autoimmune attack. He originally applied these ideas to prion disease itself (Cashman et al, Cell 1990; Paramithiotis et al, Nat Med 2003). He has applied the prion concept to developing novel immunotherapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). For ALS, he discovered that misfolded Cu/Zn superoxide dismutase (SOD1) acquires the prion-like ability to template misfolding of healthy SOD1 molecules (Grad et al, PNAS 2011), and that prion-like transmission of SOD1 misfolding can be 10 Invited Speakers propagated between cells by protein aggregates and exosomes (Grad et al, PNAS 2014). For AD, He discovered Aβ oligomer-specific epitopes; which will enable a safe and effective AD treatment (Silverman et al, ACS Chem Neurosci 2018, Gibbs et al Sci Rep 2019). He is the Scientific Founder
Load more

Recommended publications
  • The Brain and Mind Centre Optymise Cohort: Tracking Multidimensional Outcomes in Young People Presenting for Mental Healthcare
    Open access Cohort profile BMJ Open: first published as 10.1136/bmjopen-2019-030985 on 29 March 2020. Downloaded from Cohort profile: the Brain and Mind Centre Optymise cohort: tracking multidimensional outcomes in young people presenting for mental healthcare Joanne S Carpenter ,1 Frank Iorfino ,1 Shane Cross ,1,2 Alissa Nichles,1 Natalia Zmicerevska ,1 Jacob J Crouse ,1 Jake R Palmer ,1,3 Alexis E Whitton,1 Django White,1 Sharon L Naismith,1,2,4 Adam J Guastella,1 Daniel F Hermens ,1,5 Jan Scott ,1,6,7 Elizabeth M Scott ,1,8 Ian B Hickie 1 To cite: Carpenter JS, Iorfino F, ABSTRACT Strengths and limitations of this study Cross S, et al. Cohort profile: Purpose The Brain and Mind Centre (BMC) Optymise the Brain and Mind Centre cohort assesses multiple clinical and functional domains ► This cohort tracks longitudinally a large number of Optymise cohort: tracking longitudinally in young people presenting for mental health multidimensional outcomes in young people presenting for mental health care and care and treatment. Longitudinal tracking of this cohort will young people presenting for treatment early in the course of common mental allow investigation of the relationships between multiple mental healthcare. BMJ Open disorders. It will provide detailed information about outcome domains across the course of care. Subsets of 2020;10:e030985. doi:10.1136/ variations in the course of emerging illness over a have completed detailed neuropsychological bmjopen-2019-030985 Optymise prolonged, and developmentally sensitive, follow-up and neurobiological assessments, permitting investigation period. ► Prepublication history and of associations between these measures and longitudinal additional material for this ► Multiple clinical and functional outcome domains course.
    [Show full text]
  • Research Excellence
    Research excellence We are one of the world’s top research universities and a member of Australia’s prestigious Group of Eight network and the Association of Pacific Rim Universities. We also partner with others that excel in research, including Harvard, Stanford, Utrecht University, Tsinghua University and the University of Hong Kong. sydney.edu.au/research Our research is driven by the big such as health, climate change and − the Australian Institute for picture and we provide a hub for food security. Our multidisciplinary Nanoscale Science and industry, government and community research centres include: Technology that is transforming groups to collaborate with us and Sydney into a global hub for connect with our researchers and − the Charles Perkins Centre discovering and harnessing new students. The development of major dedicated to easing the global science at the nanoscale. innovations such as the black box burden of obesity, diabetes, recorder, pacemaker, Wifi and the cardiovascular disease We invest in research that changes bionic ear started here. and related conditions the way we think about the world. − the Brain and Mind Centre, a Find out more about our research: We are also home to 90 world- leader in research, education sydney.edu.au/research renowned multidisciplinary research and treatment of a range and teaching centres that are of diseases from autism to strongly positioned to tackle some schizophrenia, depression, of the world’s biggest challenges, dementia and Parkinson’s disease In the top 50 All our research We are tripling of the world’s best is ranked at world our investment in CRICOS 00026A CRICOS research universities standard or above research (QS World University (Excellence in Research for (University of Sydney Rankings 2018) Australia report, 2015) Strategic Plan, 2016-20 ) – POSTGRADUATE RESEARCH HOW TO APPLY HOW TO APPLY RESEARCH These steps will guide you in applying for a research – master's or PhD degree at the University of Sydney.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2020-046830 on 7 July 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 27, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-046830 on 7 July 2021. Downloaded from Repetitive transcranial magnetic stimulation (rTMS) in autism spectrum disorder: protocol for a multicentre randomised controlled clinical trial ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-046830 Article Type: Protocol Date Submitted by the 11-Nov-2020 Author: Complete List of Authors: Enticott,
    [Show full text]
  • Measuring Social Anxiety in Adults with Autism Spectrum Disorder: Psychometric
    Running head: PSYCHOMETRIC PROPERTIES OF SOCIAL ANXIETY MEASURES IN ASD Measuring Social Anxiety in Adults with Autism Spectrum Disorder: Psychometric Properties of Self-Report Instruments Authors: Kelsie A. Boulton1,2, & Adam J. Guastella1,2 1. Autism Clinic for Translational Research, Brain and Mind Centre, Children’s Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, 2050, Australia. 2. Child Neurodevelopment and Mental Health Team, Brain and Mind Centre, Children’s Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, 2050, Australia. Please address correspondence to: Prof Adam Guastella Brain & Mind Centre The University of Sydney 100 Mallett Street Camperdown, NSW 2050 Australia [email protected] PSYCHOMETRIC PROPERTIES OF SOCIAL ANXIETY MEASURES IN ASD 2 Abstract Adults with autism spectrum disorder (ASD) are at elevated risk for social anxiety disorder (SAD). Limited information exists on the appropriateness of using social anxiety instruments with these adults. This study examines psychometric properties of self-report social anxiety instruments in autistic adults without intellectual disability, compared to adults with SAD. Additionally, we compared instrument scores between autistic adults with a dual diagnosis of SAD and adults with SAD only. Adults diagnosed with SAD (N=316) or ASD (N=102) were recruited from the Brain and Mind Centre in New South Wales, Australia. Sixty autistic participants received a diagnosis of SAD. Participants completed the Liebowitz Social Anxiety Scale-self-report, the Social Interaction Anxiety Scale, the Social Phobia Scale, and the Brief Fear of Negative Evaluation Scale. All instruments showed excellent internal consistency in autistic adults.
    [Show full text]
  • Brain and Mind Centre Annual Report
    Our sydney.edu.au Brain and Mind Centre Annual Report 2015-16 patients’ success sydney.edu.au/brain-mind sydney.edu.au/brain-mind 0774 2 9351 +61 The University of Sydney Contact us is our greatest reward. Forest Stewardship Council (FSC®) is a globally recognised certification Forest Stewardship Council (FSC®) is a globally recognised certification overseeing all fibre sourcing standards. This provides guarantees for the consumer that products are made of woodchips from well-managed forests and other controlled sources with strict environmental, economical and social standards. Contents Welcome ............................................ 2 Co-Directors...........................................2 Message from Vice Chancellors ...............3 - Overview ............................................ 4 Teams and key research themes ..............4 Partnerships ...........................................6 - Child Development and Behaviour ......... 8 Our core business ...................................9 Highlights .............................................. 10 Key projects and clinical trials ............... 12 2017 and beyond ................................... 13 Key publications .................................... 14 - Youth Mental Health ............................ 18 Our core business ................................. 18 Brain and Mind Centre Annual Report 2015-16 Highlights ..............................................20 2017 and beyond ...................................22 Key projects and clinical trials ..............23 Key
    [Show full text]
  • The University of Sydney Health and Wellness
    The University of Sydney Health and Wellness Presented by Dr Sarah Robbins Faculty of Medicine and Health Institute of Bone and Joint research The University of Sydney Page 1 Why collaborate with The University of Sydney? Established in 1850, we are Australia’s first university. – Today we are ranked in the world’s top 50 universities. – More than 20 of our subjects are ranked in the world’s top 30. – Our research in every area is ranked as performing at world standard or above. Last year we received more than $350 million in government funding for research. – We currently have 60,000 students including nearly 26,000 international students from more than 130 countries. The University of Sydney Page 2 – 320,000+ alumni in more than 170 countries. Who do we currently collaborate with? The University of Sydney Page 3 What are we doing about? – We are tripling our research investment to $150 million per year by 2020 to enable our academic staf to improve the lives of people in Australia and around the world. – Since 2011 we have invested more than $1.7 billion in exceptional facilities, and we are home to a cluster of research centres that supports multidisciplinary, collaborative projects. – By 2020, we aim to give 50 percent of our students the opportunity to study overseas during their degree. The University of Sydney Page 4 Our world-class research centres – The Charles Perkins Centre is dedicated to easing the global burden of obesity, diabetes and cardiovascular disease. – Sydney Nano is transforming our city into a global hub for discovering and harnessing new science at the nanoscale.
    [Show full text]
  • Brain Communications Ain Communications
    doi:10.1093/braincomms/fcaa235 BRAIN COMMUNICATIONS 2021: Page 1 of 8 | 1 BRAINAIN COMMUNICATIONSCOMMUNICATIONS Cerebrospinal fluid liquid biopsy for detecting Downloaded from https://academic.oup.com/braincomms/article/3/1/fcaa235/6105078 by University of Melbourne user on 26 March 2021 somatic mosaicism in brain Zimeng Ye,1 Zac Chatterton,2 Jahnvi Pflueger,3,4 John A. Damiano,1 Lara McQuillan,1 Anthony Simon Harvey,5,6,7 Stephen Malone,8 Hongdo Do,9,10,11 Wirginia Maixner,12 Amy Schneider,1 Bernadette Nolan,8 Martin Wood,13 Wei Shern Lee,5,6 Greta Gillies,5,6 Kate Pope,5 Michael Wilson,5,6 Paul J. Lockhart,5,6 Alexander Dobrovic,10,11,14,* Ingrid E. Scheffer,1,5,6,7 Melanie Bahlo,15,16 Richard J. Leventer,5,6,7 Ryan Lister,3,4 Samuel F. Berkovic,1,† and Michael S. Hildebrand1,5,† * Present address: Department of Medicine (Austin Health), Translational Genomics and Epigenomics Laboratory, University of Melbourne, Melbourne, Victoria 3084, Australia † These authors contributed equally to this work. Brain somatic mutations are an increasingly recognized cause of epilepsy, brain malformations and autism spectrum disorders and may be a hidden cause of other neurodevelopmental and neurodegenerative disorders. At present, brain mosaicism can be detected only in the rare situations of autopsy or brain biopsy. Liquid biopsy using cell-free DNA derived from cerebrospinal fluid has detected somatic mutations in malignant brain tumours. Here, we asked if cerebrospinal fluid liquid biopsy can be used to detect somatic mosaicism in non-malignant brain diseases. First, we reliably quantified cerebrospinal fluid cell-free DNA in 28 patients with focal epilepsy and 28 controls using droplet digital PCR.
    [Show full text]
  • Witness Statement of Professor David Leon Copolov Ao
    WIT.0001.0184.0001 Royal Commission into Victoria's Mental Health System WITNESS STATEMENT OF PROFESSOR DAVID LEON COPOLOV AO I, David Leon Copolov, Professor of Psychiatry, Monash University and Pro-Vice-Chancellor, Major Campuses and Student Engagement, of Monash University, Wellington Road, Clayton, Victoria 3800, say as follows: I make this statement in my private professional capacity as a psychiatrist, academic and former researcher, the long-standing Executive Director of the Mental Health Research Institute of Victoria (from 1985-2004) and my previous governance experience as a Director of the Board of the Royal Women’s Hospital (my term having ended on 30 June 2020) and on the Board of the Peter MacCallum Cancer Centre, with six years (2007- 2013) as Deputy Chairman of that Board and five years (2005-2010) as Chair of the Research Committee of that Board. My experience, since 2009, in Senior Management at Monash University, Australia’s largest university, has also guided my views and recommendations about ‘big system’ reform in the area of mental health. My opinions are not to be interpreted as being provided on behalf of Monash University, the University of Melbourne or any other institution or organisation that I am or have been associated with. 2 As detailed below, I do not have experience on the frontline of the public mental health system. However, I have had extensive peer contact with colleagues in the public mental health system, and am an ardent (but unappointed) advocate for those who are served by and who work in that system. I am also an aggregator of information from people associated with and documentary sources relating to the Victorian public mental health sector.
    [Show full text]
  • Non-Government Funding for Victorian Health and Medical Research About Research Australia
    NON-GOVERNMENT FUNDING FOR VICTORIAN HEALTH AND MEDICAL RESEARCH ABOUT RESEARCH AUSTRALIA OUR VISION: Research Australia envisions a world where Australia unlocks the full potential of its world-leading health and medical research sector to deliver the best possible healthcare and global leadership in health innovation. OUR MISSION: To use our unique convening power to position health and medical research as a significant driver of a healthy population and contributor to a healthy economy. OUR ROLE: CONNECT researchers, funders and consumers to increase investment in health and medical research from all sources. ENGAGE Australia in a conversation about the health benefits and economic value of its investment in health and medical research. INFLUENCE government policies that support effective health and medical research and its routine translation into evidence-based practices and better health outcomes. ACKNOWLEDGMENT: Research Australia acknowledges the support of the Victorian Government Department of Health and Human Services in the preparation of this report. This document and the ideas and concepts set out in this document are subject to copyright. No part of this document, ideas or concepts are to be reproduced or used either in identical or modified form, without the express written consent of Research Australia Limited ABN 28 095 324 379. Published December 2018 2 RESEARCH AUSTRALIA Non-government funding for Victorian Health and Medical Research 3 3 GLOSSARY ACNC Australian Charities and Not-for-profits Commission CAH Charity Advancing Health - a subtype of charity, used by the ACNC to register charities GDP Gross Domestic product - a measure of value of economic activity HPC Health Promotion Charity - a subtype of charity, used by the ACNC to register charities.
    [Show full text]
  • CHIEF EXECUTIVE OFFICER Australian National Imaging Facility
    CHIEF EXECUTIVE OFFICER Australian National Imaging Facility Closing date: April 11, 2021 Administering organisation Nodes of NIF CONTENTS Letter from the Chair, NIF Board 3 About the Australian National Imaging Facility 4 NIF Governance and Management 7 Duty Statement 8 How to Apply 10 The University of Queensland: Administering Organisation of NIF 11 Why choose Brisbane, Australia? 12 LETTER FROM THE CHAIR, AUSTRALIAN NATIONAL IMAGING FACILITY (NIF) BOARD On behalf of the Board of NIF, and the Administering Organisation, the University of Queensland, I have great pleasure in inviting applications for the appointment as the Chief Executive Officer of NIF. NIF provides state-of-the-art imaging capabilities that support world-class science for the Australian research and innovation communities. The facility provides critical infrastructure and capability to address national and global challenges in medicine, human health, food security and new materials. NIF is looking for an innovative, collaborative, inclusive and inspiring leader to lead the next stage of the organisation’s development. The successful candidate will be a strategic thinker, with strong business acumen, able to harness diverse interests, with experience in delivering outcomes at scale. He or she will have a proven track record of building collaborative partnerships with various stakeholders, and a deep understanding of navigating the nuances of Government, academia and industry. A science and technology background that provides the basis for strong and influential engagement with the imaging community and outstanding and persuasive communication and presentation skills are essential for the role. The successful candidate will be expected to play a significant national and international role to promote NIF especially in solving current and emerging national priorities in the post COVID social and economic recovery.
    [Show full text]
  • 113 a Case of Suspected Autoimmune Encephalitis Secondary to Nivolumab
    Abstracts J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-anzan.100 on 29 July 2019. Downloaded from Results Out of the 235 patients that were reviewed, 71 112 AXONAL POLYNEUROPATHY WITH ONSET IN YOUNG patients either received thrombolysis and/or were sent for ADULTHOOD DUE TO TUBB3 MUTATION endovascular treatment, and 164 patients were not suitable for Po Sheng Yang*, Kimberley K Forrest, Ian B Wilson. Neurology, Cairns Base Hospital, hyperacute treatment. Using the triage tool, we identified that Cairns, QLD, Australia 26% (n=61) of the rapid clinical assessment and 32% (n=42) of CT perfusion scans performed could have been avoided. 10.1136/jnnp-2019-anzan.99 Conclusion Use of a web-based triage tool is not only effective to identify patients suitable for hyperacute management but Introduction The TUBB3 gene encodes the protein Beta-tubu- also to avoid over-investigation and prioritize rapid neurologi- lin isotype III, a component of the microtubule cytoskeleton. cal clinical assessments. Mutations in this gene have been associated with axonal poly- neuropathy, however usually associated with congenital fibrosis of the extraocular muscles (CFOEM) and other abnormalities of cerebral development.12We report a case of isolated neu- 111 RECURRENT HEADACHES WITH PSYCHOSIS, CSF ropathy associated with a TUBB3 mutation. LYMPHOCYTOSIS, VESSEL BEADING AND Methods Case report - clinical information and next genera- PAPILLOEDEMA- AUTOIMMUNE/VIRAL ENCEPHALITIS tion sequencing results were obtained. WITH VASCULOPATHY OR UNUSUAL PRESENTATION OF Results A 64 year old man presented with a severe, progres- REVERSIBLE CEREBRAL VASOCONSTRICTION sive, length dependent sensorimotor polyneuropathy which SYNDROME (RCVS)? commenced in his late twenties.
    [Show full text]
  • Recommendations for Designing Health Information Technologies For
    JOURNAL OF MEDICAL INTERNET RESEARCH Cheng et al Original Paper Recommendations for Designing Health Information Technologies for Mental Health Drawn From Self-Determination Theory and Co-design With Culturally Diverse Populations: Template Analysis Vanessa Wan Sze Cheng, PhD; Sarah E Piper, GradDip, Psych(Hons); Antonia Ottavio, DipHthSc, BN; Tracey A Davenport, BA(Hons), eMBA; Ian B Hickie, AM, MD, FRANZCP, FASSA Brain and Mind Centre, The University of Sydney, Sydney, Australia Corresponding Author: Vanessa Wan Sze Cheng, PhD Brain and Mind Centre The University of Sydney 94 Mallett Street Camperdown Sydney, 2050 Australia Phone: 61 93510774 Email: [email protected] Abstract Background: Culturally diverse populations (including Aboriginal and Torres Strait Islander people, people of diverse genders and sexualities, and culturally and linguistically diverse people) in nonurban areas face compounded barriers to accessing mental health care. Health information technologies (HITs) show promising potential to overcome these barriers. Objective: This study aims to identify how best to improve a mental health and well-being HIT for culturally diverse Australians in nonurban areas. Methods: We conducted 10 co-design workshops (N=105 participants) in primary youth mental health services across predominantly nonurban areas of Australia and conducted template analysis on the workshop outputs. Owing to local (including service) demographics, the workshop participants naturalistically reflected culturally diverse groups. Results: We identified 4 main themes: control, usability, affirmation, and health service delivery factors. The first 3 themes overlap with the 3 basic needs postulated by self-determination theory (autonomy, competence, and relatedness) and describe participant recommendations on how to design an HIT. The final theme includes barriers to adopting HITs for mental health care and how HITs can be used to support care coordination and delivery.
    [Show full text]